Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasburicase for Hyperuricemia in Tumor Lysis Syndrome
NCT00230217Phase 4Completed
- Sponsor
- Sanofi
- Start
- Mar 2004
- Primary completion
- Jul 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of rasburicase in hyperuricemia, tumor lysis syndrome (TLS), sponsored by Sanofi. Started Mar 2004; status: completed.
02
Drugs
rasburicase
03
Conditions
hyperuricemiatumor lysis syndrome (TLS)
Beyond the preview
Go deeper on NCT00230217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230217.